DK1965823T3 - Fremgangsmåder til indgivelse af hypoglykæmiske midler - Google Patents

Fremgangsmåder til indgivelse af hypoglykæmiske midler Download PDF

Info

Publication number
DK1965823T3
DK1965823T3 DK06839697.7T DK06839697T DK1965823T3 DK 1965823 T3 DK1965823 T3 DK 1965823T3 DK 06839697 T DK06839697 T DK 06839697T DK 1965823 T3 DK1965823 T3 DK 1965823T3
Authority
DK
Denmark
Prior art keywords
glp
use according
agonist composition
composition
polypeptide
Prior art date
Application number
DK06839697.7T
Other languages
English (en)
Inventor
Mark A Bush
Mary Colleen O'neill
Original Assignee
Glaxosmithkline Llc Corp Service Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38024051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1965823(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc Corp Service Company filed Critical Glaxosmithkline Llc Corp Service Company
Application granted granted Critical
Publication of DK1965823T3 publication Critical patent/DK1965823T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Claims (21)

1. Glucagon-lignende peptid-(GLP-l)-agonistsammensætning omfattende mindst ét polypeptid, der har GLP-l-aktivitet, til anvendelse i en fremgangsmåde til behandling af Type-1 diabetes, Type-II diabetes, fedme eller hyperglykæmi, kendetegnet ved, at sammensætningen indgives subkutant via en injektionsindretning omfattende et rør, der har en nål-gauge på 28 eller højere, og hvor sammensætningen indgives én gang ugentligt, og yderligere, hvor sammensætningen omfatter 0,01 mg til 104 mg af polypeptidet, der har GLP-l-aktivitet.
2. GLP-l-agonistsammensætning til anvendelse ifølge krav 1, omfattende mindst to G LP-1-fragmenter eller -varianter, hvor de mindst to G LP-1-fragmenter eller -varianter er tandem-orienteret.
3. GLP-l-agonistsammensætning til anvendelse ifølge krav 1, hvor det mindst éne polypeptid omfatter GLP-1 eller et fragment, en variant eller et konjugat deraf.
4. GLP-l-agonistsammensætning til anvendelse ifølge krav 3, hvor det mindst éne polypeptid yderligere omfatter humant serumalbumin.
5. GLP-l-agonistsammensætning til anvendelse ifølge krav 4, hvor det humane serumalbumin er genetisk splejset sammen med nævnte GLP-1 eller fragmentet eller varianten deraf.
6. GLP-l-agonistsammensætning til anvendelse ifølge et hvilket som helst af krav 3 til 5, hvor GLP-1-fragmentet eller -varianten deraf omfatter GLP-1(7-36(A8G)).
7. GLP-l-agonistsammensætning til anvendelse ifølge krav 6, hvor GLP-1-fragmentet eller -varianten deraf omfatter mindst to GLP-1(7-36(A8G)) tandem-orienteret og genetisk splejset sammen med det humane serumalbumin.
8. GLP-l-agonistsammensætning til anvendelse ifølge krav 7, hvor de mindst to GLP-1(7-36(A8G)) er genetisk splejset sammen ved N-terminalen af det humane serumalbumin.
9. GLP-l-agonistsammensætning til anvendelse ifølge et hvilket som helst foregående krav, hvor mindst ét polypeptid, der har GLP-l-aktivitet omfatter SEQ ID NO: 1.
10. GLP-l-agonistsammensætning til anvendelse ifølge et hvilket som helst foregående krav, hvor GLP-l-agonistsammensætningen er frysetørret.
11. GLP-l-agonistsammensætning til anvendelse ifølge krav 10, yderligere omfattende at iblande GLP-l-agonistsammensætningen en væske forud for indgivelse af GLP-l-agonistsammensætningen.
12. GLP-l-agonistsammensætning til anvendelse ifølge et hvilket som helst foregående krav, hvor GLP-l-agonistsammensætningen er i væskeform.
13. GLP-l-agonistsammensætning til anvendelse ifølge et hvilket som helst foregående krav, hvor GLP-l-agonistsammensætningen indgives via selv-indgivelse.
14. GLP-l-agonistsammensætning til anvendelse ifølge et hvilket som helst foregående krav, hvor injektionsindretningen er genanvendelig.
15. GLP-l-agonistsammensætning til anvendelse ifølge et hvilket som helst foregående krav, hvor injektionsindretningen er en engangsvare.
16. GLP-l-agonistsammensætning til anvendelse ifølge et hvilket som helst foregående krav, hvor injektionsindretningen omfatter en nål.
17. GLP-l-agonistsammensætning til anvendelse ifølge et hvilket som helst foregående krav, hvor injektionsindretningen omfatter et kateter.
18. GLP-l-agonistsammensætning til anvendelse ifølge krav 1, hvor mindst ét poly-peptid, der har GLP-l-aktivitet, indgives i en dosis på omkring 0,25 mg til omkring 32 mg ugentligt.
19. GLP-l-agonistsammensætning til anvendelse ifølge et hvilket som helst foregående krav, yderligere omfattende trinnet af at co-indgive en forbindelse valgt fra gruppen af: peroxisom-prolifererende-aktiveret receptor-ligand, thiazolidindion, metformin, insulin, og sulfonylurea.
20. Injektionsindretning omfattende et rør, der har en gauge på 28 eller højere og yderligere omfattende en GLP-l-agonistsammensætning til anvendelse ifølge et hvilket som helst af krav 1 til 19.
21. GLP-l-agonistsammensætning til anvendelse ifølge et hvilket som helst af krav 1 til 19, hvor sygdommen erType-II diabetes.
DK06839697.7T 2005-11-04 2006-11-03 Fremgangsmåder til indgivelse af hypoglykæmiske midler DK1965823T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73392005P 2005-11-04 2005-11-04
US74260005P 2005-12-06 2005-12-06
PCT/US2006/060508 WO2007056681A2 (en) 2005-11-04 2006-11-03 Methods for administering hypoglycemic agents

Publications (1)

Publication Number Publication Date
DK1965823T3 true DK1965823T3 (da) 2016-08-22

Family

ID=38024051

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06839697.7T DK1965823T3 (da) 2005-11-04 2006-11-03 Fremgangsmåder til indgivelse af hypoglykæmiske midler

Country Status (13)

Country Link
US (4) US8202837B2 (da)
EP (2) EP3095456A1 (da)
JP (2) JP2009514900A (da)
CY (1) CY1118007T1 (da)
DK (1) DK1965823T3 (da)
ES (1) ES2586236T3 (da)
HR (1) HRP20160866T1 (da)
HU (2) HUE029798T2 (da)
LT (2) LT1965823T (da)
PL (1) PL1965823T3 (da)
PT (1) PT1965823T (da)
SI (1) SI1965823T1 (da)
WO (1) WO2007056681A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
CA2476589C (en) 2002-02-27 2014-02-25 Pharmain, Ltd. Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
HUE029798T2 (en) 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods of administering hypoglycemic agents
EP1971372B1 (en) 2005-12-19 2018-11-14 PharmaIN Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
TWI430806B (zh) * 2006-09-13 2014-03-21 Smithkline Beecham Corp 用於投與長效降血糖藥劑之方法
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
JP2010530962A (ja) * 2007-06-12 2010-09-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 血漿においてタンパク質を検出する方法
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
PL2373681T3 (pl) * 2008-12-10 2017-07-31 Glaxosmithkline Llc Kompozycje farmaceutyczne albiglutydu
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
EP2566502A4 (en) * 2010-05-04 2013-10-09 Glaxosmithkline Llc METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
CA2827033A1 (en) * 2011-02-09 2012-08-16 Glaxosmithkline Llc Lyophilized formulations
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
RU2663587C2 (ru) * 2013-03-06 2018-08-07 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Клетки-хозяева и способы использования
MX365465B (es) 2013-03-21 2019-06-04 Sanofi Aventis Deutschland Sintesis de productos peptidicos que contienen imida ciclica.
HUE034308T2 (en) 2013-03-21 2018-02-28 Sanofi Aventis Deutschland Preparation of hydantoin-containing peptide products
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
CN117241821B (zh) * 2022-03-25 2024-04-09 北京质肽生物医药科技有限公司 多肽缀合物的药物组合物及其使用方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313439A (en) 1980-03-24 1982-02-02 Biotek, Inc. Automated, spring-powered medicament infusion system
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK134691D0 (da) 1991-07-12 1991-07-12 Novo Nordisk As Apparat
US5536249A (en) * 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US6629963B2 (en) * 1996-06-20 2003-10-07 Becton, Dickinson And Company Syringe and needle shield assembly and method of sterilizing such assembly
US6146361A (en) * 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
AR022368A1 (es) * 1998-08-28 2002-09-04 Lilly Co Eli Procedimiento para administrar peptidos insulinotropicos
US20030087820A1 (en) 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US6843781B2 (en) * 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
US6776776B2 (en) * 1999-10-14 2004-08-17 Becton, Dickinson And Company Prefillable intradermal delivery device
US6569143B2 (en) * 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
CZ308214B6 (cs) * 2000-12-07 2020-03-04 Eli Lilly And Company GLP-1 fúzní proteiny
JP2004521093A (ja) * 2000-12-13 2004-07-15 イーライ・リリー・アンド・カンパニー グルカゴン様インスリン刺激性ペプチドを用いる長期治療計画
WO2002098348A2 (en) * 2001-06-01 2002-12-12 Eli Lilly And Company Glp-1 formulations with protracted time action
CN1363654A (zh) 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
US7235063B2 (en) * 2001-08-21 2007-06-26 D'antonio Consultants International, Inc. Hypodermic injection system
EP1432730A4 (en) * 2001-08-23 2006-10-11 Lilly Co Eli GLP-1 ANALOGUES (GLUCAGON-LIKE PEPTIDE 1)
WO2003059934A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2261250B1 (en) * 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
WO2003058203A2 (en) * 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
TWI314464B (en) 2002-06-24 2009-09-11 Alza Corp Reusable, spring driven autoinjector
US7164005B2 (en) * 2002-10-17 2007-01-16 Alkermes, Inc. Microencapsulation and sustained release of biologically active polypeptides
JP5591434B2 (ja) 2002-12-20 2014-09-17 ゼリス ファーマシューティカルズ インコーポレイテッド 皮内注射方法
NZ571243A (en) * 2002-12-31 2010-04-30 Altus Pharmaceuticals Inc Complexes of protein crystals and ionic polymers comprising human growth hormone and protamine
CA2513213C (en) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP1592471B1 (en) 2003-02-04 2011-03-23 Novo Nordisk A/S Injection device with rotatable dose setting mechanism
KR100758755B1 (ko) 2003-06-12 2007-09-14 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 유사체 융합 단백질
CN101665538A (zh) * 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
HUE027902T2 (en) * 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
RS50670B (sr) * 2004-05-21 2010-06-30 Novartis Vaccines And Diagnostics Inc. Supstitucionisani derivati hinolina kao mitotički kinezinski inhibitori
US7076987B2 (en) * 2004-08-05 2006-07-18 Becton, Dickinson And Company Method of producing tapered or pointed cannula
US8183340B2 (en) 2005-05-13 2012-05-22 Eli Lilly And Company GLP-1 pegylated compounds
JP5198261B2 (ja) 2005-06-06 2013-05-15 カムルス エービー Ｇｌｐ−１類似体製剤
HUE029798T2 (en) 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods of administering hypoglycemic agents
TWI430806B (zh) 2006-09-13 2014-03-21 Smithkline Beecham Corp 用於投與長效降血糖藥劑之方法

Also Published As

Publication number Publication date
JP2014159431A (ja) 2014-09-04
HUS1600047I1 (hu) 2017-01-30
ES2586236T3 (es) 2016-10-13
EP1965823A4 (en) 2010-08-04
CY1118007T1 (el) 2017-05-17
SI1965823T1 (sl) 2016-09-30
US20130225489A1 (en) 2013-08-29
PL1965823T3 (pl) 2017-08-31
US8202837B2 (en) 2012-06-19
US20130231282A1 (en) 2013-09-05
EP1965823A2 (en) 2008-09-10
LT1965823T (lt) 2016-10-10
JP2009514900A (ja) 2009-04-09
WO2007056681A3 (en) 2008-04-10
PT1965823T (pt) 2016-08-18
EP3095456A1 (en) 2016-11-23
WO2007056681A2 (en) 2007-05-18
EP1965823B1 (en) 2016-05-18
HRP20160866T1 (hr) 2016-10-07
HUE029798T2 (en) 2017-03-28
US20160022781A1 (en) 2016-01-28
LTPA2016032I1 (lt) 2016-12-12
US20080254087A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
DK1965823T3 (da) Fremgangsmåder til indgivelse af hypoglykæmiske midler
Yu et al. Battle of GLP-1 delivery technologies
Cheang et al. Glucagon‐like peptide‐1 (GLP‐1)‐based therapeutics: current status and future opportunities beyond type 2 diabetes
DeYoung et al. Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes
TWI494121B (zh) 胰島素及ｇｌｐ－１作用劑之組合
US8338369B2 (en) Methods for administering long-lasting hypoglycemic agents
US20230414773A1 (en) Elp fusion proteins for controlled and sustained release
CA2856967A1 (en) Therapeutic agents comprising insulin amino acid sequences
TW201138762A (en) Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
EP1711532A2 (en) Combined use of a glp-1 agonist and gastrin compounds
Pechenov et al. Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery
Flatt et al. Recent advances in antidiabetic drug therapies targeting the enteroinsular axis
Bethel et al. Insulin analogues: new therapies for type 2 diabetes mellitus
Chen et al. An overview of hypoglycemic biological drugs
Alharbi A mini review on glucagon-like peptide-1 receptor agonists and its role in blood pressure regulation
Kesavadev et al. Newer Insulins on the Horizon
Ghanghas et al. G LP-1 Analogues: Monotherapy
Plengvidhya Novel Therapeutic Approach of Type 2 Diabetes Mellitus